Levels of RF and anti-CCP (median (IQR)) in patients positive for one or both of these antibodies in the two treatment groups
| P-group (n=97) | NoP-group (n=100) | p Value between groups | p Value between groups, only patients with dose according to protocol (77 vs 94) | |
|---|---|---|---|---|
| RF, baseline (IU/mL) | 12.0 (1.3–58.0) | 21.5 (1.9–80.5) | 0.39 | 0.91 |
| Anti-CCP, baseline (AU/mL) | 28.0 (3.4–367.0) | 43.5 (2.5–384.5) | 0.63 | 0.38 |
| RF, 2 years | 4.1 (0.7–28.0) | 9.5 (1.00–52.0) | 0.14 | 0.41 |
| Anti-CCP, 2 years | 13.0 (2.3–141.0) | 24.0 (2.1–446.0) | 0.70 | 1.00 |
| Δ RF, 0–2 years | −1.1 (−20.3–0.20)** | −1.5 (−34.0–0)** | 0.63 | 0.69 |
| Δ Anti-CCP, 0–2 years | −1.9 (−55.4 to −0.10)** | −0.3 (−88.0–0.5)* | 0.14 | 0.028 |
Statistically significant values are shown in bold typeface.
*p<0.05, **p<0.001 (Wilcoxon matched pairs test).CCP, cyclic citrullinated peptide 2; RF, rheumatoid factor.